Reference pricing with evidence development: A way forward for proton therapy

Journal of Clinical Oncology

Volumn 32, Issue 15, 2014, Pages 1540-1542

  Bekelman, Justin E ^a   Hahn, Stephen M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLUE CROSS BLUE SHIELD; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER THERAPY; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; EXPERIMENTAL THERAPY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG CANCER; MEDICAL SOCIETY; MEDICARE; NOTE; PRIORITY JOURNAL; PROSTATE CANCER; PROTON THERAPY; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; REIMBURSEMENT; UNITED STATES; ARTICLE; COST BENEFIT ANALYSIS; ECONOMICS; EVIDENCE BASED MEDICINE; FINANCIAL MANAGEMENT; GOVERNMENT REGULATION; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; LEGAL ASPECT; MASS COMMUNICATION;

COMPARATIVE EFFECTIVENESS RESEARCH; COST-BENEFIT ANALYSIS; DIFFUSION OF INNOVATION; EVIDENCE-BASED MEDICINE; FINANCING, GOVERNMENT; GOVERNMENT REGULATION; HEALTH CARE COSTS; HEALTH PLANNING; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HUMANS; PROTON THERAPY; STATE HEALTH PLANS; WASHINGTON;

EID: 84903773189     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.6613     Document Type: Note

References (12)

1. Winslow R, Martin T: Cancer therapy under attack: Some insurers will no longer cover the use of expensive proton beams to battle prostate cancer. Wall Street Journal, August 29, 2013:B:1
2. Ollendorf DA, Colby JA: Proton Beam Therapy: Evidence Report. Washington State Health Technology Assessment Program. http://www.hca.wa.gov/hta/pages/ proton.aspx2014
3. Rawlins M: De Testimonio: On the evidence for decisions about the use of therapeutic interventions. Clin Med 8:579-588, 2008
4. Sheehan M, Timlin C, Peach K, et al: Position statement on ethics, equipoise and research on charged particle radiation therapy. J Med Ethics [epub ahead of print on September 28, 2013]
5. Reference deleted
6. Mohr PE, Tunis SR: Access with evidence development: The US experience. Pharmacoeconomics 28:153-162, 2010
7. Tunis SR, Pearson SD: Coverage options for promising technologies: Medicare's 'coverage with evidence development.' Health Aff (Millwood) 25:1218-1230, 2006 (Pubitemid 44497620)
8. Welch HG, Mogielnicki J: Presumed benefit: Lessons from the American experience with marrow transplantation for breast cancer. BMJ 324:1088-1092, 2002 (Pubitemid 34492822)
9. Suplee C: Blue Cross agrees to fund breast cancer experiment: Women to undergo bone-marrow transplants. Washington Post, November 13, 1990:A:1
10. Steinberg EP, Tunis S, Shapiro D: Insurance coverage for experimental technologies. Health Aff (Millwood) 14:143-158, 1995
11. Pearson SD, Bach PB: How Medicare could use comparative effectiveness research in deciding on new coverage and reimbursement. Health Aff (Millwood) 29:1796-1804, 2010
12. Pearson SD, Miller FG, Emanuel EJ: Medicare's requirement for research participation as a condition of coverage: Is it ethical? JAMA 296:988-991, 2006 (Pubitemid 44285376)